A Phase 2 interventional study of MMB in Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis and Postessential Thrombocythemia (Post-ET) Myelofibrosis, sponsored by Sierra Oncology LLC - a GSK company. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.
Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one is the 11th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 7th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
GlaxoSmithKline · Sites in United States, Canada, France and 3 more countries
Ages 18+
SWOG Cancer Research Network
Ages 18+
By country, each count listing its studies:
momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 138 across the 12 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Sierra Oncology LLC - a GSK company, one of the names counted as GlaxoSmithKline. Under that name alone:
Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
11 studies in Primary Myelofibrosis by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 11 studies in Primary Myelofibrosis by GlaxoSmithKline, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 2, and was the 7th registered.
GlaxoSmithKline’s Primary Myelofibrosis studies by the year they started, since 2009.
2 of the studies testing momelotinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03441113GlaxoSmithKlineExtended Access of Momelotinib in Adults With Myelofibrosis | 2026-12-11 |
| NCT06517875GlaxoSmithKlineStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | 2027-03-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing momelotinib in Primary Myelofibrosis, from their registry updates:
Among GlaxoSmithKline’s 11 in Primary Myelofibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
Key Inclusion Criteria:
Acceptable organ function as evidenced by the following:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMB for 24 weeks (± 7 days)
Drug: MMB
Momelotinib (MMB) tablet administered orally once daily
Also known as: GS-0387, CYT387
Transfusion Independence Response by Week 24
The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.
Time frame: From baseline to Week 24
Transfusion Response Rate by Week 24
The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.
Time frame: From baseline to Week 24
Splenic Response Rate at Week 24
The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.
Time frame: Measured at Week 24
Response Rate in Total Symptom Score (TSS) at Week 24
The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.
Time frame: Measured at Week 24
Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change
Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.
Time frame: At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin
Median hepcidin at trough was assessed predose at each study visit.
Time frame: At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Serum Iron
Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Hemoglobin
Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity
Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Reticulocytes
Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%
Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Erythropoietin
Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 8 and 20
Change in Markers of Iron Metabolism and Anemia - Erythrocytes
Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Hematocrit
Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Ferritin
Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor
Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation
Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity
Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Platelets
Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Leukocytes
Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24
Change in Markers of Iron Metabolism and Anemia - Blasts
Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2 and 4
Change in Liver Iron Content
Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: Measured at Week 24
Change in Pharmacodynamics Biomarker - pSTAT3
Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).
Time frame: On Day 1 and at Weeks 4 and 24
Change in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio
Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).
Time frame: On Day 1 and at Weeks 4 and 24
Change in Inflammatory Markers - C-Reactive Protein (CRP)
Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
Time frame: At Weeks 2, 12 and 24
This study enrolled transfusion-dependent myelofibrosis patients at oncology centers in the United States and Canada. Following completion of the 24-week study period, patients who were benefiting had the option to continue maintenance momelotinib treatment in an open-label extension study (NCT02124746).
| Milestone | Momelotinib (MMB) |
|---|---|
| Started | 41 |
| Completed | 25 |
| Not completed | 16 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Adverse event | 4 |
| Withdrew: Physician decision | 4 |
| Withdrew: Death | 2 |
| Withdrew: Disease progression | 1 |
The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.
| percentage of subjects | Total |
|---|---|
| Transfusion Independence Response by Week 24 | 34.1 (22.0 to 48.1) |
The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.
| percentage of subjects | Total |
|---|---|
| Transfusion Response Rate by Week 24 | 39.0 (26.2 to 53.1) |
The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.
| percentage of subjects | Total |
|---|---|
| Splenic Response Rate at Week 24 | 12.2 (4.9 to 23.9) |
The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.
| percentage of subjects | Total |
|---|---|
| Response Rate in Total Symptom Score (TSS) at Week 24 | 15.8 (7.1 to 28.8) |
Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.
| nM | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Baseline | -1.7 (-2.1 to 4.7) | 0.1 (-3.3 to 4.5) | 0.0 (-3.3 to 4.6) |
| Day 1 | -4.8 (-10.2 to -1.4) | -11.2 (-16.0 to -5.8) | -8.6 (-14.4 to -3.3) |
| Week 2 | -4.9 (-9.1 to -0.4) | -6.7 (-11.3 to -1.2) | -6.3 (-9.2 to -0.7) |
| Week 4 | -2.6 (-8.5 to 0.1) | -7.4 (-9.6 to -0.9) | -5.4 (-9.6 to 0.1) |
| Week 8 | -2.9 (-7.3 to -0.9) | -5.2 (-17.7 to 2.1) | -4.4 (-10.9 to -0.6) |
| Week 12 | -1.4 (-6.8 to 0.7) | -5.7 (-8.7 to -0.9) | -4.1 (-8.4 to 0.5) |
| Week 16 | -0.4 (-6.4 to 0.7) | -4.3 (-15.1 to 1.9) | -2.7 (-8.5 to 1.1) |
| Week 20 | 0.0 (-6.6 to 4.2) | -7.8 (-12.5 to -1.9) | -5.3 (-9.0 to 1.5) |
| Week 24 | -1.0 (-4.6 to 0.1) | -1.8 (-7.8 to 0.1) | -1.4 (-6.0 to 0.1) |
Median hepcidin at trough was assessed predose at each study visit.
| nM | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Baseline | 22.0 (9.6 to 33.9) | 42.4 (27.4 to 64.9) | 36.6 (18.6 to 48.5) |
| Day 1 | 19.7 (5.5 to 30.8) | 43.7 (29.9 to 58.7) | 36.5 (22.4 to 48.0) |
| Week 2 | 25.1 (14.6 to 29.7) | 52.1 (37.4 to 61.2) | 38.4 (25.8 to 57.6) |
| Week 4 | 19.8 (13.7 to 30.8) | 46.4 (39.1 to 57.1) | 37.6 (19.8 to 51.9) |
| Week 8 | 16.6 (10.1 to 29.2) | 51.7 (39.9 to 59.4) | 35.5 (16.9 to 52.7) |
| Week 12 | 21.3 (10.9 to 30.4) | 44.7 (23.3 to 53.9) | 30.4 (15.6 to 44.8) |
| Week 16 | 16.9 (7.1 to 29.0) | 51.9 (43.7 to 62.9) | 34.5 (17.1 to 51.9) |
| Week 20 | 13.4 (4.5 to 27.4) | 44.2 (31.5 to 49.7) | 27.5 (13.4 to 44.3) |
| Week 24 | 15.5 (4.9 to 28.8) | 51.5 (27.9 to 60.2) | 28.4 (14.2 to 45.2) |
Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 4.5 (-14.6 to 73.2) | 5.9 (-10.3 to 31.0) | 5.9 (-11.8 to 39.6) |
| Week 4 | 39.8 (1.8 to 108.1) | 5.7 (-16.2 to 33.3) | 13.3 (-12.7 to 57.8) |
| Week 8 | 9.3 (-23.6 to 44.0) | 5.4 (-15.6 to 42.0) | 6.4 (-18.2 to 44.0) |
| Week 12 | 3.0 (-25.2 to 73.2) | 14.3 (3.1 to 35.1) | 12.8 (-7.9 to 39.4) |
| Week 16 | -15.5 (-20.3 to 56.6) | 16.5 (-19.3 to 30.7) | 8.9 (-19.4 to 30.7) |
| Week 20 | -11.1 (-17.8 to 41.7) | 9.9 (-7.4 to 28.1) | 1.9 (-17.8 to 34.6) |
| Week 24 | -8.1 (-20.4 to 45.1) | -5.1 (-24.3 to 31.1) | -6.6 (-22.9 to 37.4) |
Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change in from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 12.8 (0.0 to 20.3) | 9.2 (0.0 to 26.3) | 9.9 (0.0 to 20.4) |
| Week 4 | 8.3 (1.4 to 15.9) | 6.3 (-1.2 to 20.6) | 6.9 (-1.2 to 20.6) |
| Week 8 | 12.4 (4.8 to 27.7) | 0.4 (-7.7 to 14.2) | 5.6 (-6.3 to 19.1) |
| Week 12 | 15.6 (5.3 to 25.3) | 4.5 (-12.5 to 13.4) | 7.5 (-4.8 to 17.4) |
| Week 16 | 12.3 (4.8 to 32.9) | 0.6 (-9.5 to 15.0) | 10.2 (-6.3 to 19.7) |
| Week 20 | 13.1 (5.3 to 28.9) | 6.9 (-7.1 to 17.3) | 7.4 (-3.9 to 17.9) |
| Week 24 | 10.0 (-2.1 to 29.4) | 5.8 (-1.3 to 14.4) | 7.9 (-1.4 to 17.6) |
Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 4.5 (0.4 to 13.6) | 2.0 (-5.5 to 8.9) | 2.8 (-1.6 to 10.1) |
| Week 4 | 6.7 (-2.5 to 15.7) | 1.5 (-9.6 to 10.7) | 2.2 (-5.6 to 11.0) |
| Week 8 | 4.9 (-2.7 to 10.3) | 0.6 (-7.4 to 13.7) | 2.4 (-6.6 to 11.5) |
| Week 12 | 6.6 (-3.9 to 12.6) | 2.4 (-5.9 to 20.2) | 6.6 (-5.5 to 15.1) |
| Week 16 | 4.5 (-3.2 to 9.8) | 1.5 (-10.0 to 14.2) | 3.6 (-5.3 to 11.3) |
| Week 20 | 15.5 (3.4 to 22.1) | 5.5 (-11.6 to 15.4) | 10.6 (1.6 to 17.2) |
| Week 24 | 7.3 (3.6 to 15.8) | 0.5 (-8.4 to 10.7) | 5.5 (-5.9 to 13.0) |
Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 33.6 (-6.7 to 67.5) | -9.6 (-26.0 to 26.4) | 2.9 (-23.6 to 36.2) |
| Week 4 | 11.8 (4.0 to 40.7) | 5.5 (-32.7 to 46.4) | 7.5 (-29.3 to 43.5) |
| Week 8 | 30.0 (13.2 to 35.0) | -16.0 (-30.6 to 28.4) | 15.6 (-24.5 to 31.0) |
| Week 12 | 15.8 (-6.3 to 45.1) | -9.5 (-34.5 to 33.3) | 4.8 (-17.3 to 44.2) |
| Week 16 | 31.2 (-22.1 to 58.5) | 8.8 (-24.0 to 35.5) | 18.3 (-23.1 to 45.6) |
| Week 20 | 34.0 (-35.6 to 70.4) | 7.7 (-48.6 to 27.7) | 16.3 (-44.8 to 48.1) |
| Week 24 | 29.9 (11.5 to 58.3) | -0.6 (-32.0 to 67.8) | 24.1 (-12.0 to 58.4) |
Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 30.0 (-16.7 to 42.6) | -16.3 (-30.1 to 23.6) | -8.0 (-28.1 to 36.4) |
| Week 4 | 8.2 (-7.0 to 20.4) | 1.5 (-36.3 to 29.6) | 4.1 (-29.9 to 26.5) |
| Week 8 | 12.4 (-5.6 to 33.3) | -11.1 (-35.3 to 27.8) | 0.0 (-21.2 to 27.8) |
| Week 12 | 3.6 (-11.1 to 16.7) | 0.0 (-31.6 to 42.3) | 0.0 (-29.4 to 42.3) |
| Week 16 | 4.4 (-22.9 to 33.3) | 18.7 (-30.0 to 50.0) | 7.8 (-29.0 to 41.7) |
| Week 20 | 2.2 (-34.3 to 21.4) | 14.6 (-43.8 to 46.2) | 11.1 (-42.1 to 46.2) |
| Week 24 | 2.2 (-2.9 to 24.1) | -7.8 (-34.2 to 72.6) | -2.6 (-11.8 to 72.2) |
Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 8 | -30.8 (-55.6 to -6.8) | -8.1 (-47.7 to 31.3) | -24.5 (-55.4 to 29.4) |
| Week 20 | -45.0 (-63.4 to -2.0) | 8.5 (-16.2 to 82.9) | -4.4 (-60.2 to 32.5) |
Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 5.2 (0.0 to 20.0) | 3.4 (-6.1 to 12.1) | 3.4 (-6.1 to 16.7) |
| Week 4 | 6.7 (-8.8 to 13.3) | 3.6 (-3.6 to 21.5) | 3.8 (-3.7 to 16.0) |
| Week 8 | 3.6 (-2.0 to 23.3) | 0.0 (-13.1 to 13.0) | 3.0 (-6.1 to 22.9) |
| Week 12 | 3.1 (-3.6 to 26.7) | 3.6 (-13.8 to 11.4) | 3.4 (-10.0 to 23.1) |
| Week 16 | 0.0 (-8.8 to 26.7) | -6.9 (-9.2 to 6.5) | -2.9 (-8.8 to 12.0) |
| Week 20 | -3.3 (-12.0 to 26.7) | -3.4 (-13.8 to 7.7) | -3.4 (-12.1 to 12.2) |
| Week 24 | -8.0 (-9.7 to 26.7) | 3.3 (-7.1 to 11.4) | 0.0 (-9.7 to 19.2) |
Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 8.9 (-4.3 to 18.5) | 4.0 (-4.8 to 11.1) | 4.5 (-4.8 to 16.1) |
| Week 4 | 7.4 (-5.6 to 10.7) | 0.0 (-4.3 to 21.4) | 3.4 (-4.3 to 20.0) |
| Week 8 | 11.1 (3.6 to 25.9) | -1.7 (-14.6 to 14.8) | 4.0 (-7.1 to 17.9) |
| Week 12 | 7.1 (-3.1 to 30.8) | 1.8 (-13.0 to 14.8) | 3.6 (-8.0 to 18.2) |
| Week 16 | 5.9 (-3.2 to 28.6) | -4.2 (-8.3 to 8.2) | 3.8 (-7.7 to 10.7) |
| Week 20 | 7.1 (-3.2 to 26.9) | 0.0 (-12.0 to 4.3) | 0.0 (-7.9 to 12.8) |
| Week 24 | 8.0 (-3.6 to 28.6) | 2.3 (-9.1 to 9.1) | 4.5 (-8.3 to 14.8) |
Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 11.6 (-11.2 to 35.9) | 8.8 (-0.2 to 25.3) | 8.8 (-7.4 to 31.0) |
| Week 4 | 19.1 (-6.8 to 32.9) | 8.3 (-3.5 to 38.8) | 13.6 (-3.8 to 35.3) |
| Week 8 | 4.0 (-24.1 to 15.9) | 30.4 (-5.6 to 38.7) | 16.7 (-10.1 to 32.5) |
| Week 12 | -0.6 (-11.2 to 11.3) | 26.4 (4.3 to 52.0) | 11.3 (-10.0 to 31.0) |
| Week 16 | 0.1 (-24.6 to 8.0) | 21.6 (0.7 to 100.9) | 6.7 (-8.7 to 30.9) |
| Week 20 | 3.5 (-42.9 to 23.1) | 13.6 (-10.0 to 74.6) | 7.0 (-33.6 to 61.8) |
| Week 24 | -14.2 (-40.2 to 6.6) | 15.4 (-20.7 to 59.7) | 1.4 (-27.2 to 42.6) |
Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 4.0 (-14.7 to 18.1) | -4.9 (-12.8 to 6.3) | -4.8 (-14.1 to 16.7) |
| Week 4 | -1.4 (-7.0 to 26.2) | 8.8 (-16.6 to 31.5) | 0.7 (-16.6 to 30.9) |
| Week 8 | 6.7 (-15.3 to 24.0) | 11.0 (-15.1 to 37.2) | 7.4 (-15.3 to 28.4) |
| Week 12 | 0.8 (-18.3 to 13.5) | 11.1 (2.0 to 38.8) | 10.7 (-13.5 to 23.9) |
| Week 16 | -0.1 (-17.3 to 19.2) | 14.9 (-9.1 to 32.3) | 1.3 (-9.1 to 27.3) |
| Week 20 | -1.8 (-11.2 to 10.6) | -0.7 (-7.4 to 21.2) | -1.2 (-11.2 to 14.1) |
| Week 24 | -3.5 (-15.5 to 10.0) | 19.7 (-24.2 to 30.8) | -1.8 (-16.7 to 26.1) |
Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 2.4 (-15.2 to 52.1) | 13.5 (-6.7 to 35.6) | 10.3 (-8.3 to 44.1) |
| Week 4 | 36.4 (4.2 to 75.0) | 9.7 (-17.2 to 36.7) | 10.5 (-4.8 to 45.8) |
| Week 8 | 9.5 (-21.7 to 33.3) | -5.0 (-23.1 to 26.2) | -3.1 (-22.4 to 29.7) |
| Week 12 | 11.9 (-18.6 to 52.9) | 16.4 (-3.8 to 26.3) | 14.1 (-18.3 to 26.7) |
| Week 16 | -7.2 (-22.2 to 40.7) | -13.5 (-24.6 to 33.3) | -10.4 (-24.6 to 40.7) |
| Week 20 | -2.5 (-20.7 to 36.4) | -20.8 (-40.4 to 8.3) | -13.3 (-31.9 to 9.3) |
| Week 24 | -8.3 (-22.1 to 23.7) | -20.8 (-31.7 to 25.0) | -11.9 (-25.0 to 25.0) |
Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 0.0 (-39.4 to 13.2) | -5.1 (-31.1 to 14.6) | 0.0 (-31.5 to 13.2) |
| Week 4 | -4.0 (-24.3 to 1.9) | 0.0 (-35.7 to 34.0) | -1.0 (-25.3 to 28.1) |
| Week 8 | 6.4 (-25.0 to 28.0) | 0.0 (-40.2 to 31.8) | 0.0 (-29.9 to 28.4) |
| Week 12 | 2.9 (-17.4 to 31.4) | -18.4 (-33.6 to 7.0) | -1.6 (-32.3 to 21.4) |
| Week 16 | 4.3 (-22.4 to 34.7) | 0.0 (-49.2 to 21.4) | 2.6 (-35.6 to 30.5) |
| Week 20 | 16.5 (-12.0 to 62.8) | 5.1 (-39.8 to 44.0) | 14.2 (-15.9 to 46.7) |
| Week 24 | 12.0 (2.5 to 32.2) | 6.9 (-35.7 to 64.9) | 12.0 (-11.3 to 64.9) |
Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 21.4 (-25.4 to 48.9) | -24.4 (-41.8 to 6.3) | -9.5 (-37.4 to 32.1) |
| Week 4 | 0.0 (-25.5 to 49.1) | -29.7 (-43.7 to -4.1) | -26.3 (-35.9 to 9.6) |
| Week 8 | 19.7 (-1.3 to 57.2) | -33.6 (-48.2 to 3.3) | -12.0 (-40.3 to 23.0) |
| Week 12 | 24.1 (7.9 to 83.7) | -27.7 (-49.0 to -11.5) | -11.4 (-39.9 to 27.3) |
| Week 16 | 17.8 (2.3 to 80.0) | -26.1 (-48.0 to -6.2) | -6.2 (-31.3 to 30.8) |
| Week 20 | 31.0 (-6.9 to 41.4) | -36.2 (-67.1 to -10.7) | -14.3 (-37.8 to 34.3) |
| Week 24 | 38.9 (-15.4 to 78.3) | -22.5 (-52.1 to -8.8) | -15.3 (-30.2 to 60.9) |
Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 11.6 (-10.0 to 42.9) | -24.9 (-34.8 to 1.5) | -14.9 (-29.8 to 11.4) |
| Week 4 | 6.8 (-18.3 to 38.6) | -4.7 (-26.4 to 11.4) | 0.7 (-21.1 to 19.8) |
| Week 8 | 34.3 (11.6 to 57.1) | -0.9 (-18.9 to 13.4) | 8.9 (-14.0 to 30.5) |
| Week 12 | 8.0 (5.4 to 48.4) | -15.4 (-35.5 to 22.9) | 5.4 (-24.2 to 38.7) |
| Week 16 | 42.0 (14.6 to 53.7) | -6.7 (-26.9 to 27.0) | 15.2 (-14.3 to 45.7) |
| Week 20 | 44.7 (13.0 to 70.5) | -27.5 (-42.1 to 24.8) | 16.3 (-32.8 to 49.1) |
| Week 24 | 53.0 (0.2 to 75.3) | 18.3 (-35.4 to 42.9) | 27.1 (-26.4 to 63.4) |
Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | 0 (NA to NA) | 3.0 (3.0 to 3.0) | 3.0 (3.0 to 3.0) |
| Week 4 | 0 (NA to NA) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Change in Liver Iron Content | 4.7 (-18.4 to 25.0) | 53.3 (20.6 to 86.2) | 22.3 (-6.0 to 71.7) |
Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Day 1 - 2 hours postdose | -15.8 (-34.2 to -11.6) | -13.5 (-24.4 to -7.6) | -14.3 (-27.7 to -9.6) |
| Day 1 - 4 hours postdose | -17.1 (-23.4 to -8.1) | -10.6 (-30.6 to -2.4) | -12.8 (-27.3 to -6.6) |
| Day 1 - 6 hours postdose | -9.0 (-16.9 to -4.0) | -4.3 (-16.9 to 0.3) | -7.1 (-16.9 to -2.2) |
| Week 4 - predose | -0.9 (-2.0 to 1.8) | -2.9 (-5.5 to 17.7) | -2.0 (-5.5 to 17.7) |
| Week 4 - 2 hours postdose | -18.9 (-21.9 to -6.6) | -20.0 (-25.7 to -7.4) | -20.0 (-25.7 to -6.6) |
| Week 4 - 4 hours postdose | -19.8 (-30.4 to -8.8) | -14.1 (-28.7 to -6.1) | -14.1 (-30.4 to -6.1) |
| Week 4 - 6 hours postdose | -12.1 (-29.0 to -1.5) | -9.1 (-12.9 to 4.9) | -9.1 (-19.0 to 4.9) |
| Week 24 - predose | -4.6 (-22.9 to 0.1) | -0.3 (-7.9 to 5.1) | -2.8 (-22.9 to 5.1) |
| Week 24 - 2 hours postdose | -31.2 (-51.2 to -18.0) | -10.7 (-28.4 to -10.1) | -22.7 (-48.2 to -10.7) |
| Week 24 - 4 hours postdose | -30.6 (-65.8 to -17.6) | -14.4 (-22.6 to -12.9) | -22.6 (-50.1 to -14.1) |
| Week 24 - 6 hours postdose | -17.0 (-33.2 to -13.4) | -10.1 (-10.2 to -4.9) | -13.4 (-24.8 to -10.1) |
Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Day 1 - 2 hours postdose | -13.2 (-38.9 to -11.5) | -15.5 (-23.2 to 2.5) | -13.4 (-26.3 to -3.2) |
| Day 1 - 4 hours postdose | -9.6 (-23.2 to -0.5) | -9.7 (-28.0 to -2.3) | -9.7 (-23.9 to -2.3) |
| Day 1 - 6 hours postdose | -9.1 (-17.2 to -5.7) | -3.7 (-12.1 to 3.7) | -4.6 (-13.7 to 1.7) |
| Week 4 - predose | 0.5 (-5.2 to 31.8) | 5.0 (-4.3 to 39.8) | 4.8 (-5.2 to 39.8) |
| Week 4 - 2 hours postdose | -14.3 (-17.5 to 20.3) | -9.1 (-22.6 to 9.6) | -13.2 (-22.6 to 20.3) |
| Week 4 - 4 hours postdose | 3.0 (-32.9 to 118.3) | -13.4 (-23.7 to 23.9) | -13.4 (-31.5 to 38.1) |
| Week 4 - 6 hours postdose | 12.5 (-29.4 to 56.0) | -6.1 (-17.1 to 32.8) | -6.1 (-20.5 to 56.0) |
| Week 24 - predose | -5.7 (-17.4 to -3.7) | -3.5 (-8.8 to -2.8) | -4.4 (-17.4 to -2.8) |
| Week 24 - 2 hours postdose | -18.7 (-22.3 to -15.4) | -7.6 (-22.1 to -2.6) | -16.2 (-22.3 to -2.6) |
| Week 24 - 4 hours postdose | -21.4 (-27.1 to -14.3) | -11.5 (-15.4 to -9.6) | -15.4 (-27.0 to -11.5) |
| Week 24 - 6 hours postdose | -18.4 (-22.8 to -11.1) | -6.5 (-9.0 to -5.1) | -11.1 (-20.0 to -5.1) |
Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).
| % Change from baseline | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Week 2 | -68.7 (-75.6 to -43.5) | -53.7 (-76.8 to -18.5) | -55.6 (-76.3 to -29.5) |
| Week 12 | -67.8 (-73.1 to -28.2) | -43.4 (-59.6 to 22.6) | -48.9 (-70.1 to -15.6) |
| Week 24 | -59.8 (-79.1 to -44.8) | -47.1 (-68.4 to 65.3) | -54.8 (-73.8 to -30.7) |
Collected over From the first dose of momelotinib until 30 days following the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Momelotinib (MMB) | 3/41 (7.3%) | 14/41 (34.1%) | 36/41 (87.8%) |
| Event | Momelotinib (MMB) |
|---|---|
| AnemiaBlood and lymphatic system disorders | 3/41 |
| Acute kidney injuryRenal and urinary disorders | 3/41 |
| PresyncopeNervous system disorders | 2/41 |
| Lung infectionInfections and infestations | 2/41 |
| HypotensionVascular disorders | 2/41 |
| NeutropeniaBlood and lymphatic system disorders | 1/41 |
| DizzinessNervous system disorders | 1/41 |
| Metabolic encephalopathyNervous system disorders | 1/41 |
| AstheniaGeneral disorders | 1/41 |
| DeathGeneral disorders | 1/41 |
| Event | Momelotinib (MMB) |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 12/41 |
| DiarrhoeaGastrointestinal disorders | 10/41 |
| NauseaGastrointestinal disorders | 9/41 |
| FatigueGeneral disorders | 8/41 |
| VomitingGastrointestinal disorders | 7/41 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/41 |
| PruritusSkin and subcutaneous tissue disorders | 7/41 |
| Abdominal painGastrointestinal disorders | 6/41 |
| DizzinessNervous system disorders | 6/41 |
| HeadacheNervous system disorders | 6/41 |
| Age, Continuous(years) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Mean | 65 ± 10.0 | 72 ± 7.5 | 70 ± 9.0 |
| Sex: Female, Male(Participants) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 8 | 18 | 26 |
| Race/Ethnicity, Customized(Participants) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Black | 1 | 2 | 3 |
| White | 11 | 25 | 36 |
| Not Permitted | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
| Spleen Volume(cm^3) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Mean | 2132.2 ± 1439.5 | 2018.1 ± 1248.5 | 2057.1 ± 1299.8 |
| Total Symptom Score(units on a scale) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Mean | 19.00 ± 16.14 | 21.73 ± 13.97 | 20.73 ± 14.65 |
| RBC Units Transfused within 8 weeks prior to Enrollment(Units of red blood cell) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Mean | 5 ± 1.9 | 7 ± 2.2 | 6 ± 2.3 |
| Hepcidin(nM) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Median | 22.0 (9.6 to 33.9) | 42.4 (27.4 to 64.9) | 36.6 (18.6 to 48.5) |
| Serum iron(ug/dL) | Transfusion Independence Responders | Transfusion Independence Non-Responders | Total |
|---|---|---|---|
| Median | 96.0 (56.0 to 123.0) | 127.0 (105.0 to 174.0) | 119.0 (84.0 to 165.0) |
18 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Jul 2017, 17 months.
Results were first posted in Jan 2021, 3 years 6 months after primary completion. A results delay was requested in Jul 2018.
Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 17 months is below that.
Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Momelotinib
Sierra Oncology LLC - a GSK company →